Evaluating the Use of Thymoglobulin, Sirolimus, and Donor Bone Marrow With Kidney Transplantation Patients
Status:
Completed
Trial end date:
2007-03-22
Target enrollment:
Participant gender:
Summary
Patients with renal failure need chronic dialysis or a kidney transplant to survive. Most
kidney transplant patients must take medicines indefinitely to prevent their immune systems
from rejecting the kidney. Long-term exposure to these anti-rejection medicines can damage
the transplanted kidney.
The purpose of this study is to determine whether giving patients cells from the donor's bone
marrow will reduce or eliminate the need for long-term use of these anti-rejection drugs. In
addition to the donor's bone marrow cells, patients will receive the drugs thymoglobulin and
sirolimus.
A total of 20 patients will participate in this five-year study.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)